Organic Pressurized Fluid Patents (Class 424/45)
-
Patent number: 10660914Abstract: A pharmaceutical composition has a stuffy nose deblocking activity. The composition includes a hyperosmolar aqueous solution of a non-ionic osmolality adjusting agent, optionally in combination with an ionic osmolality adjusting agent, wherein the composition further includes iota-carrageenan and/or kappa-carrageenan as an active antiviral ingredient in an antivirally effective amount, with the proviso that the composition in its ready-for-use formulation contains no more than 0-1.5% w/v of the ionic osmolality adjusting agent. The composition is useful for deblocking a stuffy nose and for prophylactic or therapeutic intervention of a number of viral infections of the upper respiratory tract.Type: GrantFiled: July 12, 2016Date of Patent: May 26, 2020Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Angelika Bodenteich, Christiane Koller, Martina Morokutti-Kurz
-
Patent number: 10632266Abstract: Described herein are compositions, methods and an apparatus relating to the pulmonary delivery of an inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof.Type: GrantFiled: April 19, 2018Date of Patent: April 28, 2020Assignee: Ahkeo Ventures LLCInventors: Kelly McNeal, Brent Skoda
-
Patent number: 10610512Abstract: Provided herein are embodiments related to metered dose inhalers and formulations for such inhalers. In some embodiments, the inhalers are configured so as to allow a more comfortable experience for the subject receiving the formulation. In some embodiments, the formulation comprises various ingredients, such as terpenes and/or waxes, which can further enhance the level of comfort for the subject receiving the formulation.Type: GrantFiled: June 16, 2015Date of Patent: April 7, 2020Assignee: Island Breeze Systems CA, LLCInventors: Michael S. Hartman, James V. C. Boyles
-
Patent number: 10603262Abstract: The present invention provides a composition containing component (A): a compound represented by the formula (1) wherein each symbol is as described in the DESCRIPTION, or a salt thereof and component (B): a cationic surfactant, which is superior in the usability during rinsing, which makes the hair surface after treatment smooth and free of dry feeling, provides a uniform touch feeling from the root of the hair to the tip thereof, and can be utilized as an aqueous cosmetic.Type: GrantFiled: June 23, 2017Date of Patent: March 31, 2020Assignee: AJINOMOTO CO., INC.Inventors: Nana Haraya, Shun Kobayashi
-
Patent number: 10603268Abstract: The present invention relates to a hair composition comprising: (i) one or more polymers containing a silicone unit bearing alkoxy-(aminomethyl)-silyl functional groups; (ii) one or more nonionic fixing polymers and/or one or more anionic fixing polymers.Type: GrantFiled: January 27, 2016Date of Patent: March 31, 2020Assignee: L'OREALInventors: Gregory Plos, Nicolas Daubresse, Patrice Lerda, Valerie Favreau
-
Patent number: 10576070Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.Type: GrantFiled: May 9, 2019Date of Patent: March 3, 2020Assignee: Arbor Pharmaceuticals, LLCInventor: Hugh Greg Thomas
-
Patent number: 10576156Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.Type: GrantFiled: February 6, 2018Date of Patent: March 3, 2020Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Patent number: 10555903Abstract: The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease. The present disclosure also relates to a process for preparing the composition.Type: GrantFiled: October 13, 2017Date of Patent: February 11, 2020Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas R. Dhuppad, Ramprasad Murugan, Mahadeorao S. Rase, Franciscus Koppenhagen, Julianne Berry
-
Patent number: 10525005Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.Type: GrantFiled: December 4, 2017Date of Patent: January 7, 2020Assignee: The General Hospital CorporationInventor: David R. Elmaleh
-
Patent number: 10525006Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: GrantFiled: November 17, 2016Date of Patent: January 7, 2020Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
-
Patent number: 10493205Abstract: Core annular flow is used to enable the subcutaneous delivery of a viscous fluid such as a protein therapeutic formulation. The high-viscosity fluid is surrounded by a low-viscosity fluid, and the low-viscosity fluid lubricates the passage of the high-viscosity fluid. This allows the use of protein formulations that have a higher concentration and a higher viscosity at comparatively reduced injection forces and reduced injection times. Several different embodiments of injection devices that provide core annular flow are described herein.Type: GrantFiled: July 17, 2017Date of Patent: December 3, 2019Assignee: Battelle Memorial InstituteInventors: Eric C. Scribben, Steven M. Risser, Amy M. Heintz, Jeffrey L. Ellis, John D. Clay, Timothy M. Blum
-
Patent number: 10471040Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.Type: GrantFiled: September 30, 2015Date of Patent: November 12, 2019Assignee: Lachesis Biosciences LimitedInventor: Timothy Matthias Morgan
-
Patent number: 10449161Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.Type: GrantFiled: March 9, 2017Date of Patent: October 22, 2019Assignee: VECTURA LIMITEDInventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
-
Patent number: 10441552Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.Type: GrantFiled: March 5, 2019Date of Patent: October 15, 2019Assignee: Axim Biotechnologies, Inc.Inventors: George E. Anastassov, Lekhram Changoer, Philippus Anne Van Damme
-
Patent number: 10426713Abstract: A method of treating hair or skin with a creamy foam. The method comprises dispensing a personal care composition from a mechanical foam dispenser as a dosage of foam, applying the dosage of foam to hair or skin, and rinsing the dosage of foam from hair or skin. The personal hair composition contains a surfactant system that is substantially free of sulfate-based surfactants. The personal hair composition has a viscosity of less than 60 cP and a lather volume greater than 77 cm3.Type: GrantFiled: October 10, 2018Date of Patent: October 1, 2019Assignee: The Procter and Gamble CompanyInventors: Brian Xiaoqing Song, Ioannis Constantine Constantinides
-
Patent number: 10415001Abstract: The invention relates to mixtures having: components (a) having at least one fragrance of the formula (I) where R1=OC—R2, CH2OR3, C1-C8 open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, with R2=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 2-10 C atoms, with R3=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 1-8 C atoms, and components (b) having at least one fragrance, different from the fragrances of component a, characterized in that the weight ratio of all components (a) to all components (b) is from 1:10 to 1:10000.Type: GrantFiled: June 29, 2016Date of Patent: September 17, 2019Assignee: SYMRISE AGInventors: Erich Dilk, Edison Diaz, Pierre Kurzenne, Walter Kuhn
-
Patent number: 10398656Abstract: A composition comprising dimethyl sulfoxide (DMSO) as an effective agent useful for treating skin diseases or conditions caused by, associated with, or are complicated by microbial infection is disclosed.Type: GrantFiled: May 21, 2018Date of Patent: September 3, 2019Assignee: Veloce BioPharma, LLCInventors: Nicholas J. Caramenico, III, Joseph Capriotti, Kara Capriotti
-
Patent number: 10376525Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: February 1, 2016Date of Patent: August 13, 2019Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 10376526Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.Type: GrantFiled: September 13, 2017Date of Patent: August 13, 2019Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
-
Patent number: 10369102Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.Type: GrantFiled: April 21, 2017Date of Patent: August 6, 2019Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
-
Patent number: 10350149Abstract: Anhydrous antiperspirant composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer The present invention relates to an anhydrous composition in aerosol form containing: i) an oily phase comprising, in a physiologically acceptable medium: —at least one volatile oil, and —one or more antiperspirant active agents chosen from aluminum and/or zirconium salts, and —one or more water-insoluble film-forming block ethylenic polymers comprising a first block with a glass transition temperature (Tg) of greater than or equal to 85° C. and a second block with a Tg of less than or equal to 20° C., and ii) one or more propellants; the said oily phase containing less than 15% by weight and even more preferably less than 12% by weight of non-volatile polydimethylsiloxane relative to the total weight of the oils.Type: GrantFiled: December 18, 2014Date of Patent: July 16, 2019Assignee: L'OrealInventors: Odile Aubrun, Xavier Jalenques, Laurence Sebillotte-Arnaud
-
Patent number: 10350166Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition is disclosed, which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. Also disclosed is a method of treatment by applying the substantially surface active agent-free and substantially polymeric agent-free foamable composition.Type: GrantFiled: June 8, 2015Date of Patent: July 16, 2019Assignee: FOAMIX PHARMACEUTICALS LTD.Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
-
Patent number: 10342820Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: GrantFiled: May 30, 2012Date of Patent: July 9, 2019Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Patent number: 10342787Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.Type: GrantFiled: April 16, 2018Date of Patent: July 9, 2019Assignee: ARBOR PHARMACEUTICALS, LLCInventor: Hugh Greg Thomas
-
Patent number: 10342938Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.Type: GrantFiled: June 14, 2016Date of Patent: July 9, 2019Assignee: MannKind CorporationInventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
-
Patent number: 10342806Abstract: Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems.Type: GrantFiled: June 29, 2016Date of Patent: July 9, 2019Assignee: University of South FloridaInventors: Robert Dana Frisina, Joseph Paul Walton, Bo Ding, Xiaoxia Zhu
-
Patent number: 10335435Abstract: A method is disclosed for delivery of stem cells to the central nervous system, particularly the brain, using an intranasal, injectable approach for the treatment of neurological deficits. The injectable approach employs a syringe to inject a stem cell solution or suspension into mucosal tissue of the nose using endoscopy. The approach provides direct endoscopic visual access to mucosal and sub-mucosal tissue selected for injection and the depth of placement of stem cells within the selected mucosal and sub-mucosal tissue. Placement of stem cells solely within the mucosal and sub-mucosal tissue assures survival of the stem cells and improves the likelihood the stem cells will reach specific sites of damage within the brain. This endoscopic intranasal approach is useful as therapy for patients who may benefit from cellular therapy as a result of stroke, brain trauma, and neurodegenerative conditions.Type: GrantFiled: May 19, 2016Date of Patent: July 2, 2019Inventor: Marco Merida
-
Patent number: 10335538Abstract: A treatment method that increases circulation and pluripotency of stem and progenitor cells within a patient can be used to fight off or cure various diseases for the patient such as chronic kidney disease or end-stage renal disease. An administrator of the treatment method is provided with a medicinal-administration system such as an intravenous injection system. The treatment method begins by preparing a dosage of oxygen-ozone mixture with the medicinal-administration system. The medicinal-administration system then transfuses the oxygen-ozone mixture in the patient's bloodstream so that the renal system and/or the bone marrow can be targeted by the oxygen-ozone mixture. These steps are repeated as a plurality of treatment session for the patient.Type: GrantFiled: January 23, 2017Date of Patent: July 2, 2019Inventor: Priya Visweswaran Balakrishnan
-
Patent number: 10336868Abstract: Methods of selectively modifying lignin, polycarboxylated products thereof, and methods of deriving aromatic compounds therefrom. The methods comprise electrochemically oxidizing lignin using stable nitroxyl radicals to selectively oxidize primary hydroxyls on ?-O-4 phenylpropanoid units to corresponding carboxylic acids while leaving the secondary hydroxyls unchanged. The oxidation results in polycarboxylated lignin in the form of a polymeric ?-hydroxy acid. The polymeric ?-hydroxy acid has a high loading of carboxylic acid and can be isolated in acid form, deprotonated, and/or converted to a salt. The ?-hydroxy acid, anion, or salt can also be subjected to acidolysis to generate various aromatic monomers or oligomers. The initial oxidation of lignin to the polycarboxylated form renders the lignin more susceptible to acidolysis and thereby enhances the yield of aromatic monomers and oligomers obtained through acidolysis.Type: GrantFiled: May 27, 2016Date of Patent: July 2, 2019Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Shannon S. Stahl, Mohammad Rafiee
-
Patent number: 10328216Abstract: A method of manufacturing a flowable and dispersible powder includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution. The aqueous solution includes at least one functional excipient. The nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.Type: GrantFiled: January 20, 2017Date of Patent: June 25, 2019Assignee: Flurry Powders, LLCInventors: Andrew John Boeckl, David Edward Cookson
-
Patent number: 10323064Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.Type: GrantFiled: June 2, 2017Date of Patent: June 18, 2019Assignee: Kyungpook National University Industry—Academic Cooperation FoundationInventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
-
Patent number: 10314785Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.Type: GrantFiled: June 20, 2014Date of Patent: June 11, 2019Assignee: NORTON HEALTHCARE LTDInventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
-
Patent number: 10307342Abstract: There is provided an oral biofilm inhibitor having an exceptional inhibitory effect on oral biofilm formation. It is an oral biofilm inhibitor comprising a curable composition containing an antimicrobial agent, wherein a compressive strength of a cured product formed by curing the composition is 150 MPa or less, and a content of the antimicrobial agent is 0.001 to 3% by weight. An oral biofilm inhibitor thus obtained is used for inhibiting biofilm formation in an oral cavity by applying a curable composition containing an antimicrobial agent to a dental defect site for allowing the composition to cure at the dental defect site, and then disintegrating the cured composition.Type: GrantFiled: August 21, 2015Date of Patent: June 4, 2019Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Kazuhiro Omori, Takashi Ito, Shogo Takashiba, Masao Irie
-
Patent number: 10301255Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: July 21, 2016Date of Patent: May 28, 2019Assignee: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xuri Gao, Xiaowen Peng, Yat Sun Or
-
Patent number: 10279046Abstract: The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.Type: GrantFiled: March 6, 2014Date of Patent: May 7, 2019Assignee: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Choun-Ki Joo, Jun-Sub Choi
-
Patent number: 10258569Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).Type: GrantFiled: September 20, 2016Date of Patent: April 16, 2019Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.Inventors: Stuart Corr, Timothy James Noakes
-
Patent number: 10258547Abstract: The present invention relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, talc and one UV sunscreen ingredient. It also relates to a cosmetic composition in the foam form comprising, in a physiologically acceptable medium, at least one aqueous phase, at least 1% by weight of at least one mineral filler relative to its total weight, and one UV sunscreen ingredient.Type: GrantFiled: January 29, 2009Date of Patent: April 16, 2019Assignee: L'OREALInventor: Takehiko Kasai
-
Patent number: 10258568Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).Type: GrantFiled: August 29, 2016Date of Patent: April 16, 2019Assignee: MEXICHEM AMANCO HOLDINGS S.A. DE C.V.Inventors: Stuart Corr, Timothy James Noakes
-
Patent number: 10251900Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.Type: GrantFiled: June 13, 2018Date of Patent: April 9, 2019Assignee: INSMED INCORPORATEDInventors: Gina Eagle, Renu Gupta
-
Patent number: 10238697Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.Type: GrantFiled: April 12, 2016Date of Patent: March 26, 2019Assignee: ARES TRADING S.A.Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
-
Patent number: 10226483Abstract: The present invention generally relates to topical compositions and methods of using the same. The topical compositions may comprise a hydrophilic composition and a hydrophobic composition in admixture. The hydrophobic composition may include a nitric oxide-releasing compound such as, for example, a diazeniumdiolate functionalized co-condensed silica particle. In some embodiments, the topical composition may be self-emulsifying. Further described herein are kits comprising a hydrophilic composition and a hydrophobic composition.Type: GrantFiled: May 2, 2018Date of Patent: March 12, 2019Assignee: Novan, Inc.Inventors: Ryan Doxey, Jian Bao
-
Patent number: 10201672Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.Type: GrantFiled: July 2, 2013Date of Patent: February 12, 2019Assignee: MannKind CorporationInventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfiled, Anthony Bryant
-
Patent number: 10195139Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.Type: GrantFiled: October 11, 2012Date of Patent: February 5, 2019Assignee: Shin Nippon Biomedical Laboratories, Ltd.Inventors: Ryoichi Nagata, Shunji Haruta
-
Patent number: 10179139Abstract: Described herein is a pharmaceutical composition that includes a beta2-agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide, and, optionally, one or more pharmaceutically acceptable excipients.Type: GrantFiled: July 25, 2011Date of Patent: January 15, 2019Assignee: CIPLA LimitedInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Patent number: 10179145Abstract: A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.Type: GrantFiled: January 19, 2016Date of Patent: January 15, 2019Assignees: University of Maryland, College Park, University of Maryland, BaltimoreInventors: Matthew Dowling, John Hess, Grant Bochicchio, Srinivasa Raghavan
-
Patent number: 10166268Abstract: The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.Type: GrantFiled: July 2, 2015Date of Patent: January 1, 2019Assignee: THE GEORGE WASHINGTON UNIVERSITYInventors: David Mendelowitz, Vivek Jain, Heather Jameson, Jay Shawn Kimbro
-
Patent number: 10166247Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.Type: GrantFiled: February 8, 2017Date of Patent: January 1, 2019Assignee: AstraZeneca ABInventors: Nayna Govind, Maria Marlow
-
Patent number: 10159769Abstract: Methods of making medical devices are described. A method of making a medical device for delivering a bioactive includes preparing a suitable solution comprising the bioactive; placing a vessel containing the solution over a substrate comprising a biocompatible foam and defining open cells; initiating flow of the solution from the vessel and toward the substrate such that the solution exits the vessel and contacts the substrate; and maintaining flow of the solution for an amount of time sufficient to achieve a desired volume of the solution within the substrate. Medical devices made by the methods are also described.Type: GrantFiled: October 30, 2017Date of Patent: December 25, 2018Assignee: Cook Medical Technologies LLCInventor: Colleen Gemborys
-
Patent number: 10139321Abstract: The present disclosure relates to a mucolytic tablet for a sample collection device that causes mucolysis of biological samples collected in the sample collection device. The mucolytic tablet includes N-acetyl L-cysteine (NALC), a pharmaceutically active mucolytic agent that reduces the viscosity of mucus containing biological samples. The mucolytic tablet also includes one or more chelating agents, water-soluble anti-adherent/s, and at least one buffering agent.Type: GrantFiled: July 29, 2016Date of Patent: November 27, 2018Assignee: Alpha-Tec Systems, Inc.Inventors: Richard Williams, Anne Frontella, Mark Williams
-
Patent number: 10130573Abstract: The present invention is a composition and method of treatment for skin disorders, conditions, and severe skin dryness in general through topical systematic and periodic application of a formulation that generally may include salicylic acid, glycolic acid, urea, dimethyl isosorbide, ethoxydiglycol, barrier repair agents, anti-irritants, humectants, and also has an acidic pH formulation.Type: GrantFiled: June 19, 2017Date of Patent: November 20, 2018Assignee: Clark Pharmaceuticals LLCInventors: Stephen W. Clark, Natalie Barger